Ida-1, the caenorhabditis elegans orthologue of mammalian diabetes autoantigen IA-2, potentially acts as a common modulator between Parkinson's disease and diabetes: Role of Daf-2/Daf-16 insulin like signalling pathway

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Fatima, Soobiya ^a   Haque, Rizwanul ^a   Jadiya, Pooja ^a   Shamsuzzama, ^a   Kumar, Lalit ^a   Nazir, Aamir ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CAENORHABDITIS ELEGANS PROTEIN; DOPAMINE; DOPAMINE TRANSPORTER; INSULIN; PROTEIN IDA 1; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR DAF 16; TRANSCRIPTION FACTOR DAF 2; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; DAF-16 PROTEIN, C ELEGANS; DAF-2 PROTEIN, C ELEGANS; FORKHEAD TRANSCRIPTION FACTOR; GREEN FLUORESCENT PROTEIN; IDA-1 PROTEIN, C ELEGANS; INSULIN RECEPTOR; MEMBRANE PROTEIN; PROTEIN TYROSINE PHOSPHATASE;

ADULT; ANIMAL TISSUE; ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DIABETES MELLITUS; DNA SYNTHESIS; EMBRYO; GENE SILENCING; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TISSUE CULTURE; ANIMAL; CELL NUCLEUS; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC ANIMAL;

CAENORHABDITIS ELEGANS; MAMMALIA;

ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; CELL NUCLEUS; DIABETES MELLITUS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; GREEN FLUORESCENT PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MICROSCOPY, FLUORESCENCE; MOTOR ACTIVITY; PARKINSON DISEASE; PROTEIN TYROSINE PHOSPHATASES; RECEPTOR, INSULIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84916244792     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113986     Document Type: Article

References (36)

1. Xu Q, Park Y, Huang X, Hollenbeck A, Blair A, et al. (2011) Diabetes and risk of Parkinson's disease. Diabetes Care 34: 910-915.
2. Sivitz WI, Yorek MA (2010) Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal 12: 537-577.
3. Kaletta T, Hengartner MO (2006) Finding function in novel targets: C. elegans as a model organism. Nat Rev Drug Discov 5: 387-398.
4. Munoz-Lobato F, Rodriguez-Palero MJ, Naranjo-Galindo FJ, Shephard F, Gaffney CJ, et al. (2014) Protective role of DNJ-27/ERdj5 in Caenorhabditis elegans models of human neurodegenerative diseases. Antioxid Redox Signal 20: 217-235.
5. Schlotterer A, Kukudov G, Bozorgmehr F, Hutter H, Du X, et al. (2009) C. elegans as model for the study of high glucose-mediated life span reduction. Diabetes 58: 2450-2456.
6. http://www.wormbase.org/db/get?name5WBGene00002048;class5gene (Accessed 2014, Nov 7).
7. Lan MS, Wasserfall C, Maclaren NK, Notkins AL (1996) IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 93: 6367-6370.
8. Notkins AL (2002) Immunologic and genetic factors in type 1 diabetes. J Biol Chem 277: 43545-43548.
9. Torii S (2009) Expression and function of IA-2 family proteins, unique neuroendocrine-specific proteintyrosine phosphatases. Endocr J 56: 639-648.
10. Cai T, Fukushige T, Notkins AL, Krause M (2004) Insulinoma-Associated Protein IA-2, a Vesicle Transmembrane Protein, Genetically Interacts with UNC-31/CAPS and Affects Neurosecretion in Caenorhabditis elegans. J Neurosci 24: 3115-3124.
11. Cai T, Krause MW, Odenwald WF, Toyama R, Notkins AL (2001) The IA-2 gene family: homologs in Caenorhabditis elegans, Drosophila and zebrafish. Diabetologia 44: 81-88.
12. Mahoney TR, Luo S, Nonet ML (2006) Analysis of synaptic transmission in Caenorhabditis elegans using an aldicarb-sensitivity assay. Nat Protoc 1: 1772-1777.
13. Schaffitzel E, Hertweck M (2006) Recent aging research in Caenorhabditis elegans. Exp Gerontol 41: 557-563.
14. Balch WE, Morimoto RI, Dillin A, Kelly JW (2008) Adapting proteostasis for disease intervention. Science 319: 916-919.
15. Brenner S (1974) The genetics of Caenorhabditis elegans. Genetics 77: 71-94.
16. Stiernagle T (2006) Maintenance of C. elegans. WormBook: 1-11.
17. Fraser AG, Kamath RS, Zipperlen P, Martinez-Campos M, Sohrmann M, et al. (2000) Functional genomic analysis of C. elegans chromosome I by systematic RNA interference. Nature 408: 325-330.
18. Jadiya P, Chatterjee M, Sammi SR, Kaur S, Palit G, et al. (2011) Sir-2.1 modulates 'calorie-restrictionmediated' prevention of neurodegeneration in Caenorhabditis elegans: implications for Parkinson's disease. Biochem Biophys Res Commun 413: 306-310.
19. Schulz TJ, Zarse K, Voigt A, Urban N, Birringer M, et al. (2007) Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell Metab 6: 280-293.
20. Jadiya P, Khan A, Sammi SR, Kaur S, Mir SS, et al. (2011) Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson's disease. Biochem Biophys Res Commun 413: 605-610.
21. Kaur S, Sammi SR, Jadiya P, Nazir A (2012) RNAi of cat-2, a putative tyrosine hydroxylase, increases alpha synuclein aggregation and associated effects in transgenic C. elegans. CNS Neurol Disord Drug Targets 11: 387-394.
22. Nazir A, Sammi SR, Singh P, Tripathi RK (2010) Trans-cellular introduction of HIV-1 protein Nef induces pathogenic response in Caenorhabditis elegans. PLoS One 5: e15312.
23. Jadiya P, Nazir A (2012) Environmental toxicants as extrinsic epigenetic factors for parkinsonism: studies employing transgenic C. elegans model. CNS Neurol Disord Drug Targets 11: 976-983.
24. Chiang WC, Tishkoff DX, Yang B, Wilson-Grady J, Yu X, et al. (2012) C. elegans SIRT6/7 homolog SIR-2.4 promotes DAF-16 relocalization and function during stress. PLoS Genet 8: e1002948.
25. Jadiya P, Mir SS, Nazir A (2012) Effect of various classes of pesticides on expression of stress genes in transgenic C. elegans model of Parkinson's disease. CNS Neurol Disord Drug Targets 11: 1001-1005.
26. White JG, Southgate E, Thomson JN, Brenner S (1976) The structure of the ventral nerve cord of Caenorhabditis elegans. Philos Trans R Soc Lond B Biol Sci 275: 327-348.
27. Bargmann CI, Horvitz HR (1991) Chemosensory neurons with overlapping functions direct chemotaxis to multiple chemicals in C. elegans. Neuron 7: 729-742.
28. Ward S (1973) Chemotaxis by the nematode Caenorhabditis elegans: identification of attractants and analysis of the response by use of mutants. Proc Natl Acad Sci U S A 70: 817-821.
29. Craft S, Watson GS (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3: 169-178.
30. Yen K, Narasimhan SD, Tissenbaum HA (2011) DAF-16/Forkhead box O transcription factor: many paths to a single Fork(head) in the road. Antioxid Redox Signal 14: 623-634.
31. Murphy CT, McCarroll SA, Bargmann CI, Fraser A, Kamath RS, et al. (2003) Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature 424: 277-283.
32. Lee SS, Kennedy S, Tolonen AC, Ruvkun G (2003) DAF-16 target genes that control C. elegans lifespan and metabolism. Science 300: 644-647.
33. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A (2006) Opposing activities protect against age-onset proteotoxicity. Science 313: 1604-1610.
34. Zhong W, Sternberg PW (2006) Genome-wide prediction of C. elegans genetic interactions. Science 311: 1481-1484.
35. Taylor RC, Dillin A (2011) Aging as an event of proteostasis collapse. Cold Spring Harb Perspect Biol 3.
36. Skovronsky DM, Lee VM, Trojanowski JQ (2006) Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol 1: 151-170.